RT Journal Article
SR Electronic
T1 Association of Inflammation with Depression and Anxiety: Evidence for Symptom-Specificity and Potential Causality from UK Biobank and NESDA Cohorts
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.08.20248710
DO 10.1101/2021.01.08.20248710
A1 Yuri Milaneschi
A1 Nils Kappelmann
A1 Zheng Ye
A1 Femke Lamers
A1 Sylvain Moser
A1 Peter B. Jones
A1 Stephen Burgess
A1 Brenda W. J. H. Penninx
A1 Golam M. Khandaker
YR 2021
UL http://medrxiv.org/content/early/2021/01/09/2021.01.08.20248710.abstract
AB We examined whether inflammation is uniformly associated with all depressive and anxiety symptoms, and whether these associations are potentially causal. Data was from 147,478 individuals from the UK Biobank (UKB) and 2,905 from the Netherlands Study of Depression and Anxiety (NESDA). Circulating C-reactive protein (CRP) was measured in both cohorts and interleukin-6 (IL-6) in NESDA. Genetic instruments for these proteins were obtained from published GWAS and UKB. Depressive and anxiety symptoms were assessed with self-report questionnaires. In NESDA, neurovegetative (appetite, sleep, psychomotor) symptoms were disaggregated as increased vs. decreased. In joint analyses, circulating CRP was associated with depressive symptoms of depressed mood (OR=1.06, 95%CI=1.05-1.08), altered appetite (OR=1.25, 95%CI=1.23-1.28), sleep problems (OR=1.05, 95%CI=1.04-1.06), and fatigue (OR=1.12, 95%CI=1.11-1.14), and with anxiety symptoms of irritability (OR=1.06, 95%CI=1.05-1.08) and worrying control (OR=1.03, 95%CI=1.02-1.04). Further analyses in NESDA using IL-6 as exposure confirmed associations with depressive symptoms, including anhedonia (OR=1.30, 95%CI=1.12-1.52). Both CRP (OR=1.27, 95%CI=1.13-1.43) and IL-6 (OR=1.26, 95%CI=1.07-1.49) were associated with increased sleep. CRP was associated with increased appetite (OR=1.21, 95%CI=1.08-1.35) while IL-6 with decreased appetite (OR=1.45, 95%CI=1.18-1.79). In Mendelian Randomization analyses, increased risk of fatigue (estimate=0.25, SE=0.08) and sleep problems (estimate=0.19, SE=0.07) were associated with genetically-predicted higher IL-6 activity. Inflammation was associated with core depressive symptoms of low mood and anhedonia and somatic/neurovegetative symptoms of fatigue, altered sleep and appetite changes. Less consistent associations were found for anxiety. The IL-6/IL-6R pathway could be causally linked to depression. Experimental studies are required to further evaluate causality, mechanisms, and usefulness of immunotherapies for depressive symptoms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYM is partially supported by the Complex Trait Genetics programme of Amsterdam Neuroscience. NK and SM are supported by the International Max Planck Research School of Translational Psychiatry. FL is supported by FP7 Marie Curie Career Integration Grant PCIG12 GA 2012 334065 from the European Union Seventh Framework Programme. GMK and PBJ acknowledge support from the MQ: Transforming Mental Health (Data Science Award; grant code: MQDS17/40), which also supported ZY. GMK also acknowledges funding support from the Wellcome Trust (grant code: 201486/Z/16/Z), the Medical Research Council UK (grant code: MC/PC/17213 and MR/S037675/1), and the BMA Foundation (J Moulton grant 2019). BWJHP has received research funding (unrelated to the work reported here) from Jansen Research and Boehringer Ingelheim.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UKB study was approved by the UK Biobank research ethics committee and Human Tissue Authority research tissue bank. The current analysis was approved under project no. 26999. The NESDA research protocol was approved centrally by the Vrije Universiteit (VU) Amsterdam University Medical Centre ethics committee and locally by the ethics committee of participating universities. Participants from both cohorts provided informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe provide data for genetic instruments and MR analysis scripts on the Open Science Framework under https://osf.io/2fwr6/ for full reproducibility. https://www.osf.io/2fwr6/